How Argenica’s ARG-007 Is Targeting High-Risk Stroke Patients After Safety Success

• ARG-007 met primary safety endpoint in Phase 2 AIS trial with no significant adverse events
• No overall infarct volume reduction, but 15% reduction seen in high-risk slow collateral blood flow subgroup
• Positive trends in cognition, daily independence, and quality of life at 90 days post-treatment
• Plans underway for targeted Phase 2b trial with global clinical advisors and pharmaceutical partners